Bukel Secures Tens of Millions in Series B Funding to Advance Mesh-Based Inhalation Drug Delivery Platform

VCBeat has learned that Qingdao Future Medical Technology Co., Ltd. (brand name: Bukeler, hereinafter referred to as “Bukeler”) recently secured tens of millions of yuan in Series B financing, with Jingle Capital as the investor. The funds from this round will be used for R&D investment, production capacity upgrades, and accelerating overseas market expansion.

Bukele’s headquarters is located in the beautiful coastal city of Qingdao. The company has established R&D and production bases covering 6,000 square meters in Qingdao and Changsha, and set up an international business center in Boston, USA. With years of deep expertise in vibrating mesh nebulization technology, Bukele is committed to leveraging this technology to support inhalation pharmaceutical companies in the development of specialized drug-device combination products for both innovative and generic drugs, thereby empowering these enterprises with full lifecycle management solutions for their innovative and generic inhalation therapies.

The company’s Bukèle Precision Nebulization Customization Platform provides dedicated drug-device integrated one-stop solutions to inhalation pharmaceutical companies worldwide. To date, the company has served more than 30 domestic and international enterprises specializing in inhalation formulations—including inhaled antibiotics, inhaled interferons, inhaled antibodies, and inhaled vaccines—and has achieved multiple milestones in joint development projects.

Established in 2014, the company operates a specialized nebulization inhalation laboratory and maintains both sterile and non-sterile production workshops. Its core team members possess extensive experience in the medical device industry. The company has filed more than 60 patents and holds regulatory registration expertise across multiple jurisdictions, including China (NMPA), the United States (FDA), the European Union (CE), Japan, South Korea, India, and Saudi Arabia.

Leveraging its technological expertise and team strengths, Bukele adopts a patient-centric approach. By taking into account the respiratory characteristics of different patients and patient populations, and fully integrating the physicochemical properties of inhalation formulation prescriptions with nebulizer characteristics, the company utilizes its modular platform and diverse product portfolio to provide inhalation pharmaceutical companies with one-stop solutions that integrate products, technology, and services. The aim is to enable higher pulmonary deposition with smaller drug doses in shorter nebulization times through customized nebulizer products, thereby maximizing empowerment for pharmaceutical companies while delivering a superior nebulization therapy experience for patients.

Leveraging its Clover Spray mesh nebulization technology, patented two-valve-one-canister design, and digital monitoring capabilities, the company has developed two core product lines: the VM series and the NEB series. The VM series is renowned for its high pulmonary deposition efficiency, while the NEB series emphasizes cost-effectiveness and portability. Together, these two series cater to the diverse needs of pharmaceutical companies with their distinct features.

In addition to product development, Bukale provides pharmaceutical companies specializing in inhalation formulations with comprehensive, integrated drug-device services throughout the entire product lifecycle. These services include laboratory nebulization parameter analysis and feasibility assessments for integrated drug-device solutions during the preclinical stage; custom nebulizer development, adaptive clinical trial system customization, combined drug-device regulatory registration, and intellectual property certification during the clinical trial phase; and dedicated nebulizer manufacturing, customized patient management system development and operation, and 24/7 after-sales support during the commercialization stage.

The Bukele Precision Nebulization Customization Platform offers two primary collaboration models for pharmaceutical companies specializing in inhalation formulations: the Standard Product Technical Upgrade Model and the Exclusive Product Design and Development Model, each addressing distinct pain points. The Standard Product Technical Upgrade Model is suitable for companies seeking to moderately enhance nebulizer performance while prioritizing short development cycles and low costs. The Exclusive Product Design and Development Model caters to companies requiring exclusive intellectual property rights, unique aesthetics, proprietary certificates or model numbers, and additional performance features, aiming to establish high technical barriers for their inhalation products through specialized nebulizer solutions.

Through the aforementioned collaborative models, Bukele has currently provided optimal solutions for over 30 different formulation prescriptions both domestically and internationally. Moving forward, Bukele will continue to deepen its expertise in micromesh nebulization technology and accelerate the development of specialized drugs and devices in the inhalation therapy sector.